Adipocyte-derived extracellular vesicles are key regulators of central leptin sensitivity and energy homeostasis.

Summary

Adipocyte-derived EVs carry a miRNA repertoire that sensitizes leptin signaling by suppressing negative regulators; loss of these miRNAs fosters leptin resistance in obesity. Engineered EVs targeting the CNS restored central leptin responsiveness and produced significant weight loss in obese mice, illuminating an adipose-brain axis mechanism and a therapeutic vector.

Key Findings

• Adipocyte-derived EVs contain miRNAs that enhance leptin signaling by inhibiting negative feedback regulators.
• Obesity is associated with loss of leptin-sensitizing miRNAs in Ad-EVs, contributing to leptin resistance and weight gain.
• Engineered EVs targeted to the CNS delivered leptin-sensitizing miRNAs, reversing central leptin resistance and inducing significant weight loss in obese mice.

Clinical Implications

While preclinical, the work opens a path to EV-based therapeutics aimed at reversing leptin resistance, a core barrier to obesity treatment. It also suggests biomarkers (EV miRNA signatures) for assessing leptin sensitivity and treatment response.

Limitations

• Preclinical models in mice; human safety, biodistribution, and durability are unknown.
• Potential off-target effects and immunogenicity of engineered EVs require evaluation.

Future Directions

Define EV dose, schedule, and safety in large animals; profile EV miRNA biomarkers of leptin sensitivity in humans; and initiate first-in-human studies for obesity with leptin resistance phenotyping.